{"id":"entecavir-carvedilol","safety":{"commonSideEffects":[{"rate":null,"effect":"Lactic acidosis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Hepatic decompensation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Entecavir is a nucleoside reverse transcriptase inhibitor that suppresses HBV replication by blocking viral polymerase activity. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that reduces portal pressure and decreases variceal bleeding risk in patients with advanced liver disease. The combination targets both the underlying viral infection and hemodynamic complications of cirrhosis.","oneSentence":"This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and carvedilol to block beta-adrenergic receptors, addressing both viral replication and portal hypertension complications.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:45:30.726Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B with advanced fibrosis or cirrhosis"},{"name":"Hepatitis B-related portal hypertension with variceal bleeding risk"}]},"trialDetails":[{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT02945982","phase":"PHASE4","title":"Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Fuzheng Huayu and Entecavir","status":"UNKNOWN","sponsor":"ShuGuang Hospital","startDate":"2018-04-05","conditions":"Portal Hypertension","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Entecavir+Carvedilol","genericName":"Entecavir+Carvedilol","companyName":"ShuGuang Hospital","companyId":"shuguang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and carvedilol to block beta-adrenergic receptors, addressing both viral replication and portal hypertension complications. Used for Chronic hepatitis B with advanced fibrosis or cirrhosis, Hepatitis B-related portal hypertension with variceal bleeding risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}